Skip to content

Study · Randomized controlled trial · n = 868 · 2021

8 results

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.

Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG

Diabetes, obesity & metabolism3 Jan 2021Cited by 92 (Europe PMC)

PMID33074557 (opens in a new tab)PMCIDPMC7839591 (opens in a new tab)DOI10.1111/dom.14232 (opens in a new tab)PepBankPUB-33074557
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, both doses of semaglutide reduced HbA1c more than sitagliptin after 30 weeks.

    In plain wordsIn adults with type 2 diabetes on metformin, both semaglutide doses lowered HbA1c more than sitagliptin.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at week 30
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Both doses of semaglutide were superior to sitagliptin in reducing HbA1c and body weight after 30 weeks of treatment.
    2 context sentences
    Summary · context
    The primary and confirmatory secondary endpoints were change from baseline to week 30 in HbA1c and body weight, respectively.
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, both doses of semaglutide reduced body weight more than sitagliptin after 30 weeks.

    In plain wordsIn adults with type 2 diabetes on metformin, both semaglutide doses reduced body weight more than sitagliptin.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at week 30
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Both doses of semaglutide were superior to sitagliptin in reducing HbA1c and body weight after 30 weeks of treatment.
    2 context sentences
    Summary · context
    The primary and confirmatory secondary endpoints were change from baseline to week 30 in HbA1c and body weight, respectively.
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, the odds of reaching HbA1c below 7.0% were higher with both semaglutide doses than with sitagliptin.

    In plain wordsIn adults with type 2 diabetes on metformin, more people reached HbA1c below 7.0% with semaglutide than with sitagliptin.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchieving HbA1c below 7.0%
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The odds of achieving target HbA1c  of less than 7.0% (53 mmol/mol), weight loss of 5% or higher, or 10% or higher, and the composite endpoint of HbA1c  less than 7.0% (53 mmol/mol) without severe or blood glucose-confirmed symptomatic hypoglycaemia no weight gain, were all sig…
    1 context sentence
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, the odds of a weight loss of 5% or more were higher with both semaglutide doses than with sitagliptin.

    In plain wordsIn adults with type 2 diabetes on metformin, more people lost 5% or more of body weight with semaglutide than with sitagliptin.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of 5% or more
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The odds of achieving target HbA1c  of less than 7.0% (53 mmol/mol), weight loss of 5% or higher, or 10% or higher, and the composite endpoint of HbA1c  less than 7.0% (53 mmol/mol) without severe or blood glucose-confirmed symptomatic hypoglycaemia no weight gain, were all sig…
    1 context sentence
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, the odds of a weight loss of 10% or more were higher with both semaglutide doses than with sitagliptin.

    In plain wordsIn adults with type 2 diabetes on metformin, more people lost 10% or more of body weight with semaglutide than with sitagliptin.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of 10% or more
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The odds of achieving target HbA1c  of less than 7.0% (53 mmol/mol), weight loss of 5% or higher, or 10% or higher, and the composite endpoint of HbA1c  less than 7.0% (53 mmol/mol) without severe or blood glucose-confirmed symptomatic hypoglycaemia no weight gain, were all sig…
    1 context sentence
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, the odds of the composite endpoint (HbA1c below 7.0% without severe or confirmed symptomatic hypoglycaemia and no weight gain) were higher with both semaglutide doses than with sitagliptin.

    In plain wordsIn adults with type 2 diabetes on metformin, more people met the combined HbA1c, hypoglycaemia and weight goal with semaglutide than with sitagliptin.

    Peptide
    Semaglutide
    Outcome
    IncreaseComposite: HbA1c below 7.0% without severe or symptomatic hypoglycaemia and no weight gain
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The odds of achieving target HbA1c  of less than 7.0% (53 mmol/mol), weight loss of 5% or higher, or 10% or higher, and the composite endpoint of HbA1c  less than 7.0% (53 mmol/mol) without severe or blood glucose-confirmed symptomatic hypoglycaemia no weight gain, were all sig…
    1 context sentence
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  7. 07HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on metformin, the safety profile of semaglutide was consistent with the known class effects of GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes on metformin, semaglutide safety matched what is known for its drug class.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety profile
    Study

    n = 868

    Comparator
    Sitagliptin 100 mg once daily
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    The safety profile for semaglutide was consistent with the known class effects of GLP-1 receptor agonists (RAs).
    1 context sentence
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In the Chinese subpopulation of adults with type 2 diabetes, efficacy and safety findings for semaglutide were consistent with the overall trial.

    In plain wordsIn Chinese adults with type 2 diabetes, semaglutide results matched those of the whole trial.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedEfficacy and safety in the Chinese subpopulation
    Study

    n = 605

    Comparator
    Sitagliptin 100 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg or 1.0 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Consistent efficacy and safety findings were seen in the Chinese subpopulation.
    2 context sentences
    Summary · context
    The trial enrolled ~70% (605/868) of the patients in China, and the remaining patients from four other countries, including the Republic of Korea.
    Summary · context
    In the 30-week, randomized, double-blind, double-dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%-10.5%) were randomized to receive once-weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once-daily sitagliptin 100 mg (n = 290).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03061214

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Novo Nordisk A/Sn = 86828 Aug 2017 to 15 Apr 2019

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 2 Mar 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.